Loading...
XWARMOC
Market cap38mUSD
Dec 23, Last price  
9.42PLN
1D
-4.56%
1Q
-30.43%
IPO
-67.51%
Name

Molecure SA

Chart & Performance

D1W1MN
XWAR:MOC chart
P/E
—
P/S
1,585,951.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.24%
Rev. gr., 5y
-49.35%
Revenues
0k
-99.99%
5,4006,6006,0003,0002,807122,936,4004001,613,238100
Net income
-18m
L+35.22%
-559,106-2,424,293-2,404,332-3,777,159-4,246,83267,962,632-13,642,556-13,539,992-18,308,202
CFO
-12m
L+16.12%
-1,530,239-1,440,683-599,630-4,889,462-7,107,93657,435,477-13,496,417-10,213,383-11,859,317

Profile

Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
URL
https://molecure.com/
IPO date
Apr 19, 2018
Employees
109
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
100
-99.99%
1,613
403,209.50%
400
-100.00%
Cost of revenue
1,646
9,380
9,389
Unusual Expense (Income)
NOPBT
(1,646)
(7,767)
(9,389)
NOPBT Margin
Operating Taxes
(1,724)
6
Tax Rate
NOPAT
(1,646)
(6,043)
(9,395)
Net income
(18,308)
35.22%
(13,540)
-0.75%
(13,643)
-120.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
49,100
117
4,839
BB yield
-14.96%
-0.06%
-0.93%
Debt
Debt current
2,164
2,205
1,810
Long-term debt
12,115
10,611
10,208
Deferred revenue
142
11
Other long-term liabilities
326
289
72
Net debt
(49,709)
(52,802)
(90,022)
Cash flow
Cash from operating activities
(11,859)
(10,213)
(13,496)
CAPEX
(362)
(33,631)
(18,835)
Cash from investing activities
(44,507)
(33,586)
(18,823)
Cash from financing activities
54,736
7,377
13,857
FCF
3,975
(2,721)
(16,256)
Balance
Cash
63,988
65,618
102,039
Long term investments
Excess cash
63,988
65,537
102,039
Stockholders' equity
6,522
126,448
141,144
Invested Capital
158,177
67,290
44,875
ROIC
ROCE
EV
Common stock shares outstanding
16,836
14,030
13,952
Price
19.50
36.75%
14.26
-61.87%
37.40
-26.09%
Market cap
328,302
64.10%
200,068
-61.66%
521,789
-25.60%
EV
278,593
147,266
431,767
EBITDA
202
(6,453)
(9,089)
EV/EBITDA
1,377.00
Interest
38
16
6
Interest/NOPBT